| 貨號 | 規格 | 價格 | 上海 | 北京 | 武漢 | 南京 | 購買數量 |
|---|---|---|---|---|---|---|---|
S84102-2mg |
≥99% | ￥390.00 | 貨期：2-3天 | - | - | - |
|
S84102-5mg |
≥99% | ￥690.00 | 貨期：2-3天 | - | - | - |
|
S84102-10mg |
≥99% | ￥1000.00 | 貨期：2-3天 | - | - | - |
|
S84102-25mg |
≥99% | ￥2000.00 | 貨期：2-3天 | - | - | - |
|
S84102-50mg |
≥99% | ￥3900.00 | 貨期：2-3天 | - | - | - |
|
S84102-100mg |
≥99% | ￥7400.00 | 貨期：2-3天 | - | - | - |
|
LY 344864 is a selective, orally active 5-HT1F receptor agonist with a Ki of 6 nM. LY 344864 is a full agonist producing an effect similar in magnitude to serotonin itself. LY 344864 can cross the blood brain barrier to some extent
| 產品描述： | LY 344864 is a selective, orally active 5-HT1F receptor agonist with a Ki of 6 nM. LY 344864 is a full agonist producing an effect similar in magnitude to serotonin itself. LY 344864 can cross the blood brain barrier to some extent | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點： | human 5-HT1F Receptor：0.006 μM (Ki)；human 5-HT1A Receptor：0.530 μM (Ki)；human 5-HT1B Receptor：0.549 μM (Ki)；human 5-HT1D Receptor：0.575 μM (Ki)；human 5-HT1E Receptor：1.415 μM (Ki)；human 5-HT2B Receptor：1.695 μM (Ki)；Human 5-HT2A Receptor：3.499 μM (Ki)；Human 5-HT3A Receptor：3.935 mM (Ki)；Human 5-HT7 Receptor：4.851 μM (Ki)；rat α2-adrenergic receptor：3.69 μM (Ki)；rat α1-adrenergic receptor：5.06 μM (Ki) | ||||||||||||||||||||
| 體內研究： | LY 344864 (0-10 ng/kg; p.o. or i.v.; once) inhibits neurogenic dural inflammation in rat migraine pain model. LY 344864 (1 mg/kg; i.v.; once) can cross the blood brain barrier to some extent in rats. LY 344864 (2 mg/kg; i.p.; daily for 14 days) attenuates dopaminergic neuron loss and improved behavioral endpoints in a Parkinson’s disease mouse model | ||||||||||||||||||||
| 參考文獻： | 1. Phebus LA, Johnson KW, Zgombick JM, Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brainpenetration and activity in the neurogenic dural inflammation model of migraine. Life Sci. 1997;61(21):2117-26. 2. Scholpa NE, et al. 5-HT1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease. Br J Pharmacol. 2018 Jan;175(2):348-358. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存條件： | RT | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網安備 31011702002021號
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京